XML 40 R20.htm IDEA: XBRL DOCUMENT v3.25.1
Segment Reporting
 12 Months Ended
Dec. 31, 2024
Segment Reporting [Abstract]  
Segment Reporting Disclosure Segment Reporting
The Company identifies its reportable segments based on information reviewed by the Company’s CODM. The Company operates as one operating and reportable segment, which is discovering, developing, manufacturing and commercializing innovative antibody-based therapeutics for the treatment of cancer. The Company has determined its reportable operating segment based on the management approach, which considers the internal organization and reporting used by the Company’s CODM to make decisions about allocating resources and assessing the Company’s performance. The determination of a single business segment is consistent with the consolidated financial information regularly reviewed by the CODM for purposes of assessing performance and allocating resources.

The CODM uses consolidated net loss, consistent with the amounts reported in the Company’s consolidated statements of operations to evaluate performance, forecast future period financial results and allocate resources. Total consolidated assets presented in the accompanying consolidated balance sheets also represent the segment’s total assets.

The table below summarizes the significant expenses regularly reviewed by the CODM (in thousands):

Year Ended December 31,
202420232022
Total revenue (a)$149,962 $58,749 $151,941 
Cost of product sales847 619 3,351 
Cost of manufacturing sales11,452 7,603 4,033 
Research and development expenses:
Vobramitamab duocarmazine39,809 39,217 55,381 
Lorigerlimab36,805 27,716 21,581 
MGC02824,055 14,408 — 
Preclinical antibody-drug conjugates (ADCs)18,102 11,170 12,975 
MGC02614,126 13,523 5,287 
Margetuximab10,846 16,081 26,869 
MGD0249,734 6,974 7,857 
Next-generation T-cell engagers8,421 10,464 13,335 
Retifanlimab2,129 3,452 2,156 
Enoblituzumab1,906 5,344 14,725 
Other programs11,261 18,234 46,860 
Total research and development expenses177,194 166,583 207,026 
Selling, general and administrative expenses71,047 52,188 58,949 
Other segment income, net (b)43,612 159,186 1,660 
Net loss$(66,966)$(9,058)$(119,758)
(a) Total revenue includes collaborative and other agreements, product sales, net, contract manufacturing, and government agreements.
(b) Other segment income, net includes the gain on sale of MARGENZA, interest and other income and expense, and income tax expense.

The Company operates in the United States and all material long-lived assets of the Company reside in the United States For information about the Company’s revenues, see Note 8, Revenue.